Multiple Myeloma (MM) Withdrawn Phase 1 / 2 Trials for DB00480 (Lenalidomide)

Also known as: MULTIPLE MYELOMA (MM) / Multiple myeloma / Myeloma, Multiple / Multiple Myelomas / Multiple Myeloma(MM) / Plasma cell myelomas / Myelomatosis multiple / Peripheral plasma cell myeloma / Myelomatosis / Multiple myeloma myelomatosis / Plasma cell myeloma / Myeloma / Multiple myeloma with failed remission

IndicationStatusPhase
DBCOND0040908 (Multiple Myeloma (MM))Withdrawn1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02802163Induction Therapy for Multiple Myeloma With Carfilzomib, Lenalidomide,Dexamethasone,PanobinostatTreatment
NCT02389543Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma PatientsTreatment